Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review

Expert Opinion on Drug Safety

Volumn 15, Issue 6, 2016, Pages 809-823

  De Hert, Marc ^a   Detraux, Johan ^a   Stubbs, Brendon ^b,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antipsychotic; fracture; Hyperprolactinemia; osteoporosis; prolactin; schizophrenia

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMISULPRIDE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; AROMATASE INHIBITOR; ASENAPINE; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; CLOZAPINE; CORTICOSTEROID; GLUCOCORTICOID; HEPARIN; ILOPERIDONE; IMMUNOSUPPRESSIVE AGENT; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PREDNISONE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; THYROID HORMONE; UNINDEXED DRUG; ZIPRASIDONE;

BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; DISEASE ASSOCIATION; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; MEASUREMENT; MENTAL PATIENT; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PROLACTIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; FEMALE; MALE; OSTEOPOROTIC FRACTURES;

ANTIPSYCHOTIC AGENTS; BONE DENSITY; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PROLACTIN; SCHIZOPHRENIA;

EID: 84964018989     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2016.1167873     Document Type: Review

References (128)

1. B.L.Riggs, L.J.Melton3rd, R.A.Robb, et al. Population based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res. 2004;19(12):1945–1954.
2. B.L.Clarke, S.Khosla Female reproductive system and bone. Arch Biochem Biophys. 2010;503(1):118–128.
3. M.T.Drake, B.L.Clarke, E.M.Lewiecki. The pathophysiology and treatment of osteoporosis. Clin Ther. 2015;37(8):1837–1850.
4. J.A.Cauley. Estrogen and bone health in men and women. Steroids. 2015;99(Pt A):11–15.
5. B.Stubbs, F.Gaughran, A.J.Mitchell, et al. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):126–133.
6. A.S.Nazrun, M.N.Tzar, S.A.Mokhtar, et al. A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag. 2014;10:937–948.
7. C.U.Correll, J.Detraux, J.De Lepeleire, et al. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119–136.
8. B.Stubbs, M.De Hert, A.A.Sepehry, et al. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand. 2014;130:470–86.•• Important meta-analysis as one of its aim was to quantify moderators of low bone mass in patients with schizophrenia on the basis of selected papers that specifically investigated this type of adverse events by means of adequate instruments.
9. K.-Y.Tsai, C.-C.Lee, Y.-M.Chou, et al. The risks of major osteoporotic fractures in patients with schizophrenia: a population-based 10-year follow-up study. Schizophr Res. 2014;159:322–328.
10. H.Wu, L.Deng, L.Zhao, et al. Osteoporosis associated with antipsychotic treatment in schizophrenia. Int J Endocrinol. 2013;2013:167138.
11. T.Kishimoto, M.De Hert, H.E.Carlson, et al. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry. 2012;25:415–429.
12. K.M.Abel, H.F.Heatlie, L.M.Howard, et al. Sex- and age-specific incidence of fractures in mental illness: a historical, population-based cohort study. J Clin Psychiatry. 2008;69:1398–1403.
13. U.Halbreich. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs. 2007;21:641–657.
14. M.Misra, G.I.Papakostas, A.Klibanski. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry. 2004;65:1607–1618.
15. K.Okita, N.Kanahara, M.Nishimura, et al. Second-generation antipsychotics and bone turnover in schizophrenia. Schizophr Res. 2014;157:137–141.
16. K.Partti, M.Heliövaara, O.Impivaara, et al. Skeletal status in psychotic disorders: a population-based study. Psychosom Med. 2010;72:933–940.
17. D.-U.Jung, D.L.Kelly, M.-K.Oh, et al. Bone mineral density and osteoporosis risk in older patients with schizophrenia. J Clin Psychopharmacol. 2011;31(4):406–410.
18. M.K.Javaid, R.I.G.Holt. Understanding osteoporosis. J Psychopharmacol. 2008;22:38–45.
19. P.M.Haddad, A.Wieck. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291–2314.
20. M.Lean, G.De Smedt. Schizophrenia and osteoporosis. Int Clin Psychopharmacol. 2004;19:31–35.
21. U.Naidoo, D.C.Goff, A.Klibanski. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology. 2003;28(Suppl 2):97–108.
22. M.P.K.Crews, O.D.Howes. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol. 2012;27:15–23.
23. S.M.Graham, D.Howgate, W.Anderson, et al. Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf. 2011;10:575–602.
24. T.Kishimoto, K.Watanabe, N.Shimada, et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry. 2008;69:385–391.
25. U.Halbreich, S.Palter. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull. 1996;22:447–454.
26. J.Peuskens, L.Pani, J.Detraux, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421–53.•• Offers an extensive and up-to-date overview of the prolactin physiology and hyperprolactinemia associated with classical, novel and newly approved antipsychotics, as well as its incidence, diagnosis, measurement, causes, and consequences.
27. Tseng P-T, Chen Y-W, Yeh P-Y, et al. Bone mineral density in schizophrenia: an update of current meta-analysis and literature review under guideline of PRISMA. Medicine (Baltimore) 2015;94(47):e1967.
28. P.Turrone, S.Kapur, M.V.Seeman, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry. 2002;159(1):133–135.
29. R.Arakawa, M.Okumura, H.Ito, et al. Positron emission tomography measurement of dopamine D2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychoticinduced hyperprolactinemia. J Clin Psychiatry. 2010;71(9):1131–1137.
30. J.R.Bishop, L.H.Rubin, J.L.Reilly, et al. Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. Ther Adv Psychopharmacol. 2012;2(3):95–102.
31. A.M.Meaney, V.O’Keane. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res. 2007;93(1–3):136–143.
32. R.J.Lodhi, S.Masand, A.Malik, et al. Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study. Schizophr Res. 2016;170(2–3):245–251.
33. B.C.Lupsa, K.Insogna. bone health and osteoporosis. Endocrinol Metab Clin North Am. 2015;44(3):517–530.
34. G.R.Emkey, S.Epstein. Secondary osteoporosis: pathophysiology & diagnosis. Best Pract Res Clin Endocrinol Metab. 2014;28(6):911–935.
35. R.Bernabei, A.M.Martone, E.Ortolani, et al. Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab. 2014;11(3):201–207.
36. World Health Organization (WHO). Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2003;921:1–164.
37. World Health Organization (WHO) (2007). WHO scientific group on the assessment of osteoporosis at primary health care level. Summary meeting report, 2004 May 5–7. Brussels (Belgium): WHO.
38. International Osteoporosis Foundation. [cited 12Oct 2015] Available from: http://www.iofbonehealth.org.
39. V.O’Keane. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22(2 Suppl):70–75.
40. B.Gong, G.S.Mandair, F.W.Wehrli, et al. Novel assessment tools for osteoporosis diagnosis and treatment. Curr Osteoporos Rep. 2014;12(3):357–365.
41. V.O’Keane, A.M.Meaney. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol. 2005;25(1):26–31.
42. A.M.Meaney, S.Smith, O.D.Howes, et al. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004;184:503–508.
43. W.D.Leslie. Clinical review: Ethnic differences in bone mass–clinical implications. J Clin Endocrinol Metab. 2012;97(12):4329–4340.
44. N.B.Watts, W.D.Leslie, A.J.Foldes, et al. 2013 International Society for Clinical Densitometry Position Development Conference: task force on normative databases. J Clin Densitom. 2013;16(4):472–481.
45. N.Bergemann, P.Parzer, C.Mundt, et al. High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol Med. 2008;38(8):1195–1201.
46. M.Hummer, P.Malik, R.W.Gasser, et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry. 2005;162(1):162–167.
47. V.Yoon, N.M.Maalouf, K.Sakhaee. The effects of smoking on bone metabolism. Osteoporos Int. 2012;23(8):2081–2092.
48. C.A.Calarge, S.D.Ivins, K.J.Motyl, et al. Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents. Ther Adv Psychopharmacol. 2013;3(5):278–293.
49. S.Vasikaran, R.Eastell, O.Bruyère, et al. IOF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420.
50. C.J.Bushe, A.Bradley, J.Pendlebury. A review of hyperprolactinaemia and severe mental illness: are there implications for clinical biochemistry?. Ann Clin Biochem. 2010;47(Pt 4):292–300.
51. C.van der Leeuw, S.Peeters, P.Domen, et al. bone mineral density as a marker of cumulative estrogen exposure in psychotic disorder: a 3 year follow-up study. PLoS One. 2015;10(8):e0136320.
52. B.J.Kinon, H.Liu-Seifert, V.L.Stauffer, et al. Bone loss associated with hyperprolactinemia in patients with schizophrenia. Clin Schizophr Relat Psychoses. 2013;7(3):115–123.
53. M.Byerly, T.Suppes, Q.-V.Tran, et al. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol. 2007;27(6):639–661.
54. N.Bataille-Simoneau, K.Gerland, D.Chappard, et al. Expression of prolactin receptors in human osteosarcoma cells. Biochem Biophys Res Commun. 1996;229(1):323–328.
55. D.Seriwatanachai, N.Krishnamra, J.P.Van Leeuwen. Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J Cell Biochem. 2009;107(4):677–685.
56. D.Seriwatanachai, K.Thongchote, N.Charoenphandhu, et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone. 2008;42(3):535–546.
57. J.A.Kanis, H.Johansson, A.Oden, et al. Assessment of fracture risk. Eur J Radiol. 2009;71(3):392–397.
58. J.A.Kanis, E.V.McCloskey, H.Johansson, et al. Approaches to the targeting of treatment for osteoporosis. Nat Rev Rheumatol. 2009;5(8):425–431.
59. J.A.Kanis, F.Borgstrom, C.De Laet, et al. Assessment of fracture risk. Osteoporos Int. 2005;16(6):581–589.
60. R.A.Dickson, W.M.Glazer. Neuroleptic-induced hyperprolactinemia. Schizophr Res. 1999;35(Suppl):SS75–S86.
61. A.Wyszogrodzka-Kucharska, J.Rabe-Jablonska. Vitamin D deficiency and impaired parathormone metabolism as a risk factor of low bone mineral density in patients with diagnosis of schizophrenia treated with second generation antipsychotics. Eur Neuropsychopharmacol. 2006;16(Suppl. 4):S373–4.
62. B.Stubbs, P.Gardner-Sood, S.Smith, et al. Sedentary behaviour is associated with elevated C-reactive protein levels in people with psychosis. Schizophr Res. 2015;168(1–2):461–464.
63. C.Roick, A.Fritz-Wieacker, H.Matschinger, et al. Health habits of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2007;42:268–276.
64. G.Faulkner, T.Cohn, G.Remington. Validation of a physical activity assessment tool for individuals with schizophrenia. Schizophr Res. 2006;82:225–231.
65. US Department of Health and Human Services. Physical activity guidelines for Americans. Washington: US Dept of Health and Human Services; 2016. Available from: http://health.gov/paguidelines/pdf/paguide.pdf [cited 2016 Jan13].
66. M.De Hert, D.Vancampfort, J.Detraux. Somatic problems and dual disorder patients. In: G.Dom, F.Moggi, editors. Co-occurring addictive and psychiatric disorders: a practice-based handbook from a European perspective. Berlin: Springer; 2015. p. 349–362.
67. J.De Leon, F.J.Diaz. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2–3):135–157.
68. M.Fini, F.Salamanna, F.Veronesi, et al. Role of obesity, alcohol and smoking on bone health. Front Biosci (Elite Ed). 2012;4:2686–2706.
69. J.A.Kanis, O.Johnell, A.Oden, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16(2):155–162.
70. C.H.Ko, R.L.Y.Chan, W.S.Siu, et al. Deteriorating effect on bone metabolism and microstructure by passive cigarette smoking through dual actions on osteoblast and osteoclast. Calcif Tissue Int. 2015;96(5):389–400.
71. L.Marinucci, M.Bodo, S.Balloni, et al. Sub-toxic nicotine concentrations affect extracellular matrix and growth factor signaling gene expressions in human osteoblasts. J Cell Physiol. 2014;229(12):2038–2048.
72. M.Abate, D.Vanni, A.Pantalone, et al. Cigarette smoking and musculoskeletal disorders. Muscles Ligaments Tendons J. 2013;3(2):63–69.
73. J.Li, F.-Q.Zhang, Z.-N.Du, et al. Protective effect of HO-1 transfection against ethanol-induced osteoblast damage. J Huazhong Univ Sci Technolog Med Sci. 2015;35(3):374–377.
74. N.Guañabens, A.Parés. Management of osteoporosis in liver disease. Clin Res Hepatol Gastroenterol. 2011;35(6–7):438–445.
75. K.M.Berg, H.V.Kunins, J.L.Jackson, et al. Association between alcohol consumption and both osteoporotic fracture and bone density. Am J Med. 2008;121(5):406–418.
76. L.-C.Chen, Y.-M.Bai, M.-H.Chang. Polydipsia, hyponatremia and rhabdomyolysis in schizophrenia: a case report. World J Psychiatry. 2014;4(4):150–152.
77. E.R.Hawken, J.M.Crookall, D.Reddick, et al. Mortality over a 20-year period in patients with primary polydipsia associated with schizophrenia: a retrospective study. Schizophr Res. 2009;107(2–3):128–133.
78. N.J.Delva, J.L.Crammer, S.V.Jarzylo, et al. Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol Psychiatry. 1989;26(8):781–793.
79. M.Wacker, M.F.Holick. Sunlight and Vitamin D: A global perspective for health. Dermatoendocrinol. 2013;5(1):51–108.
80. M.Belvederi Murri, M.Respino, M.Masotti, et al. Vitamin D and psychosis: mini meta-analysis. Schizophr Res. 2013;150(1):235–239.
81. M.Doknic, N.P.Maric, D.Britvic, et al. Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology. 2011;94(3):246–254.
82. M.De Hert, J.Detraux, D.Vancampfort, et al. Severe mental illness and diabetes mellitus type 2. Die Psychiatrie. 2012;9(3):159–164.
83. B.Stubbs, D.Vancampfort, M.De Hert, et al. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand. 2015;132(2):144–157.
84. V.V.Shanbhogue, D.M.Mitchell, C.J.Rosen, et al. Type 2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol. 2016;4(2):159–173.
85. A.K.Booth, A.Gutierrez-Hartmann. Signaling pathways regulating pituitary lactotrope homeostasis and tumorigenesis. Adv Exp Med Biol. 2015;846:37–59.
86. T.Dandinoğlu, S.Akarsu, L.Tekin, et al. A 22-year-old man with severe osteoporosis due to prolactinoma. J Clin Rheumatol. 2013;19(6):341–343.
87. Y.Zhao, X.Gan, P.Luo, et al. The risk of osteopenia in premenopausal women with various sellar tumors. Gynecol Endocrinol. 2012;28(12):945–948.
88. G.Mazziotti, T.Porcelli, M.Mormando, et al. Vertebral fractures in males with prolactinoma. Endocrine. 2011;39(3):288–293.
89. E.C.Naliato, M.L.Farias, G.R.Braucks, et al. Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest. 2005;28(1):12–17.
90. A.Colao, C.Di Somma, S.Loche, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf). 2000;52(3):319–327.
91. C.-H.Lin, C.-Y.Lin, T.-L.Huang, et al. Sex-specific factors for bone density in patients with schizophrenia. Int Clin Psychopharmacol. 2015;30(2):96–102.
92. M.Wang, R.Hou, J.Jian, et al. Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study. Hum Psychopharmacol. 2014;29(2):183–189.
93. H.Liu-Seifert, B.J.Kinon, J.Ahl, et al. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics. Ann N Y Acad Sci. 2004;1032:297–298.
94. G.Abraham, U.Halbreich, R.H.Friedman, et al. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res. 2003;59(1):17–18.
95. T.Takahashi, H.Uchida, M.John, et al. The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: findings from a longitudinal observational cohort. Schizophr Res. 2013;147(2–3):383–386.
96. C.-H.Lin, K.-H.Huang, Y.-C.Chang, et al. Clozapine protects bone mineral density in female patients with schizophrenia. Int J Neuropsychopharmacol. 2012;15(7):897–906.
97. E.Keely, J.P.Reiss, D.T.Drinkwater, et al. Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men. Endocr Pract. 1997;3(4):209–213.
98. P.Rey-Sánchez, J.M.Lavado-García, M.L.Canal-Macías, et al. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol. 2009;24(1):49–54.
99. C.van der Leeuw, P.Habets, P.Domen, et al. for G.R.O.U.P. Bone mineral density as a marker of cumulative endogenous estrogen exposure: relationship to background genetic risk of psychotic disorder. Schizophr Res. 2013;143(1):25–31.
100. N.Sugawara, N.Yasui-Furukori, A.Fujii, et al. No association between bone mass and prolactin levels among patients with schizophrenia. Hum Psychopharmacol. 2011;26(8):596–601.
101. T.-Y.Lee, M.-Y.Chung, H.-K.Chung, et al. Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study. Psychiatry Investig. 2010;7(4):278–284.
102. J.H.Renn, N.P.Yang, P.Chou. Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet Disord. 2010;11:35.
103. D.U.Jung, R.R.Conley, D.L.Kelly, et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry. 2006;67(9):1391–1396.
104. O.D.Howes, M.J.Wheeler, A.-M.Meaney, et al. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J Clin Psychopharmacol. 2005;25(3):259–261.
105. D.Becker, O.Liver, R.Mester, et al. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry. 2003;64(7):761–766.
106. G.Abraham, W.W.Paing, J.Kaminski, et al. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry. 2003;160(9):1618–1620.
107. A.Wyszogrodzka-Kucharska, J.Rabe-Jabłońska. [Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics]. Psychiatr Pol. 2005;39(6):1173–1184.
108. Tests and Procedures. Bone density test. [cited 2016 Jan11]. Available from: http://www.mayoclinic.org/tests-procedures/bone-density-test/basics/results/prc-20020254.
109. N.J.Crabtree, A.Arabi, L.K.Bachrach, et al. Dual-energy X-ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD pediatric official positions. J Clin Densitom. 2014;17(2):225–242.
110. S.Demirdas, K.E.Coakley, P.H.Bisschop, et al. Bone health in phenylketonuria: a systematic review and meta-analysis. Orphanet J Rare Dis. 2015 Feb;15(10):17.
111. S.W.Wade, C.Strader, L.A.Fitzpatrick, et al. Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos. 2014;9:182.
112. U.Halbreich, N.Rojansky, S.Palter, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med. 1995;57(5):485–491.
113. E.Barrett-Connor, G.A.Laughlin, H.Li, et al. The association of concurrent vitamin D and sex hormone deficiency with bone loss and fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res. 2012;27(11):2306–2313.
114. C.-S.Wu, C.-M.Chang, Y.-T.Tsai, et al. Antipsychotic treatment and the risk of hip fracture in subjects with schizophrenia: a 10-year population-based case-control study. J Clin Psychiatry. 2015;76(9):1216–1223.
115. T.L.Järvinen, K.Michaëlsson, P.Aspenberg, et al. Osteoporosis: the emperor has no clothes. J Intern Med. 2015;277(6):662–673.
116. H.J.Sørensen, S.O.W.Jensen, J.Nielsen. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol. 2013;23(8):872–878.
117. A.Hasan, P.Falkai, T.Wobrock, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44.
118. A.Hasan, P.Falkai, T.Wobrock, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–378.
119. B.Stubbs, D.Vancampfort, J.Bobes, et al. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. Acta Psychiatr Scand. 2015;132(2):122–130.
120. J.L.L.Morgan, J.L.Skulan, G.W.Gordon, et al. Rapidly assessing changes in bone mineral balance using natural stable calcium isotopes. Proc Natl Acad Sci U S A. 2012;109(25):9989–9994.
121. T.Komori. Animal models for osteoporosis. Eur J Pharmacol. 2015;759:287–294.
122. K.Panday, A.Gona, M.B.Humphrey. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014;6(5):185–202.
123. G.Mazziotti, E.Canalis, A.Giustina. Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med. 2010;123(10):877–884.
124. K.Briot, C.Roux. Glucocorticoid-induced osteoporosis. RMD Open. 2015;1(1):e000014.
125. B.Frenkel, W.White, J.Tuckermann. Glucocorticoid-induced osteoporosis. Adv Exp Med Biol. 2015;872:179–215.
126. ® (paliperidone). Highlights of prescribing information. April 2014. [cited 30Oct 2015]. Available from: http://www.invega.com/prescribing-information.
127. ® (risperidone). Highlights of prescribing information. April 2014. [cited 2015 Oct30] Available from: http://www.janssen.com/us/sites/www_janssen_com_usa/files/products-documents/risperdal.pdf.
128. P.Vestergaard, L.Rejnmark, L.Mosekilde. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int. 2006;17(6):807–816.